Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pavmed Inc (PAVM)

Pavmed Inc (PAVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,449
  • Shares Outstanding, K 11,069
  • Annual Sales, $ 2,450 K
  • Annual Income, $ -64,180 K
  • EBIT $ -55 M
  • EBITDA $ -52 M
  • 60-Month Beta 0.70
  • Price/Sales 5.72
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.94
  • Most Recent Earnings $-0.54 on 11/13/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 654.90% ( -86.66%)
  • Historical Volatility 95.04%
  • IV Percentile 94%
  • IV Rank 61.60%
  • IV High 1,034.21% on 12/30/24
  • IV Low 46.36% on 06/17/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 84
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,739
  • Open Int (30-Day) 1,418

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.60
  • Number of Estimates 1
  • High Estimate -0.60
  • Low Estimate -0.60
  • Prior Year -1.57
  • Growth Rate Est. (year over year) +61.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5719 +17.68%
on 12/24/24
1.2500 -46.16%
on 12/04/24
-0.5070 (-42.97%)
since 12/03/24
3-Month
0.5719 +17.68%
on 12/24/24
1.3161 -48.86%
on 10/04/24
-0.6220 (-48.03%)
since 10/03/24
52-Week
0.5719 +17.68%
on 12/24/24
4.2500 -84.16%
on 01/04/24
-3.4870 (-83.82%)
since 01/03/24

Most Recent Stories

More News
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference

/PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device,...

PAVM : 0.6730 (+5.16%)
LUCD : 0.8200 (+3.27%)
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection

/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PAVM : 0.6730 (+5.16%)
LUCD : 0.8200 (+3.27%)
PAVmed Provides Business Update and Second Quarter Financial Results

/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the...

PAVM : 0.6730 (+5.16%)
LUCD : 0.8200 (+3.27%)
Lucid Diagnostics Provides Business Update and Second Quarter Financial Results

/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

LUCD : 0.8200 (+3.27%)
PAVM : 0.6730 (+5.16%)
PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023

/PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the...

PAVM : 0.6730 (+5.16%)
LUCD : 0.8200 (+3.27%)
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023

/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and...

PAVM : 0.6730 (+5.16%)
LUCD : 0.8200 (+3.27%)
Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference

/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a...

PAVM : 0.6730 (+5.16%)
LUCD : 0.8200 (+3.27%)
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage

/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device,...

PAVM : 0.6730 (+5.16%)
LUCD : 0.8200 (+3.27%)
PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the...

PAVM : 0.6730 (+5.16%)
LUCD : 0.8200 (+3.27%)
PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC

/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the...

PAVM : 0.6730 (+5.16%)
LUCD : 0.8200 (+3.27%)

Business Summary

PAVmed Inc. is a medical device company. Its diversified pipeline of products address unmet clinical needs, which consists of CarpX (TM) to treat carpal tunnel syndrome; NextFlo(TM) and NextCath(TM) a disposable infusion pump; PortIO(TM) and NextCath interventional radiology and Caldus (TM) tissue ablation...

See More

Key Turning Points

3rd Resistance Point 0.9140
2nd Resistance Point 0.8370
1st Resistance Point 0.7550
Last Price 0.6730
1st Support Level 0.5960
2nd Support Level 0.5190
3rd Support Level 0.4370

See More

52-Week High 4.2500
Fibonacci 61.8% 2.8450
Fibonacci 50% 2.4109
Fibonacci 38.2% 1.9769
Last Price 0.6730
52-Week Low 0.5719

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar